Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development

Chemico-Biological Interactions

Volumn 192, Issue 1-2, 2011, Pages 65-71

  Thompson, Richard A ^a   Isin, Emre M ^a   Li, Yan ^b   Weaver, Richard ^b   Weidolf, Lars ^a   Wilson, Ian ^b   Claesson, Alf ^c   Page, Ken ^b   Dolgos, Hugues ^a   Kenna, J Gerry ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Adverse drug reaction; Hepatotoxicity; Reactive metabolite

Indexed keywords

BROMOBENZENE; CYTOCHROME P450; DRUG METABOLITE; ENFLURANE; GLITAZONE DERIVATIVE; HALOTHANE; ISOFLURANE; PARACETAMOL; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

BODY BURDEN; CONFERENCE PAPER; COVALENT BOND; DIABETES MELLITUS; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG TRANSFORMATION; HAZARD ASSESSMENT; HUMAN; IN VITRO STUDY; LIVER TOXICITY; NONHUMAN; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION;

EID: 79958047253     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.11.002     Document Type: Conference Paper

References (45)

1. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3 2004 711 715 10.1038/nrd1470 (Pubitemid 39173511)
2. P. Greaves, A. Williams, and M. Eve First dose of potential new medicines to humans: how animals help Nat. Rev. Drug Discov. 3 2004 226 236 10.1038/nrd1329 (Pubitemid 38379989)
3. S. Giri, K. Nieber, and A. Bader Hepatotoxicity and hepatic metabolism of available drugs: current problems and possible solutions in preclinical stages Expert Opin. Drug Metab. Toxicol. 6 2010 895 917 10.1517/17425251003792521
4. J.F. Waring, and M.G. Anderson Idiosyncratic toxicity: mechanistic insights gained from analysis of prior compounds Curr. Opin. Drug Discov. Devel. 8 2005 59 65 (Pubitemid 40116331)
5. J.R. Senior What is idiosyncratic hepatotoxicity? What is it not? Hepatology 47 2008 1813 1815 (Pubitemid 351945548)
6. A.S. Kalgutkar, and J.R. Soglia Minimising the potential for metabolic activation in drug discovery Expert Opin. Drug Metab. Toxicol. 1 2005 91 142 10.1517/17425255.1.1.91
7. R.G. Ulrich Idiosyncratic toxicity: a convergence of risk factors Annu. Rev. Med. 58 2007 17 34 (Pubitemid 46706498)
8. J.A. Hinson, D.W. Roberts, and L.P. James Mechanisms of acetaminophen-induced liver necrosis Handb. Exp. Pharmacol. 2010 369 405
9. D.P. Williams, and B.K. Park Idiosyncratic toxicity: the role of toxicophores and bioactivation Drug Discov. Today 8 2003 1044 1050 (Pubitemid 38018811)
10. J. Uetrecht Idiosyncratic drug reactions: current understanding [Review] Annu. Rev. Pharmacol. Toxicol. 47 2007 513 539
11. W.M. Lee Drug-induced hepatotoxicity N. Engl. J. Med. 349 2003 474 485 10.1056/NEJMra021844 (Pubitemid 36910027)
12. M.L. Greer, J. Barber, J. Eakins, and J.G. Kenna Cell based approaches for evaluation of drug-induced liver injury Toxicology 268 2010 125 131
13. Y. Masubuchi Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review Drug Metab. Pharmacokinet. 21 2006 347 356
14. K.L. Snow, and R.H. Moseley Effect of thiazolidinediones on bile acid transport in rat liver Life Sci. 80 2007 732 740 10.1016/j.lfs.2006.11.001 (Pubitemid 46107994)
15. R.A. Roth, and P.E. Ganey Intrinsic versus idiosyncratic drug-induced hepatotoxicity - two villains or one? J. Pharmacol. Exp. Ther. 332 2010 692 697
16. W. Tang, and A.Y.H. Lu Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective Drug Metab. Rev. 42 2010 225 249
17. S. Russmann, G.A. Kullak-Ublick, and I. Grattagliano Current concepts of mechanisms in drug-induced hepatotoxicity Curr. Med. Chem. 16 2009 3041 3053
18. D.C. Evans, A.P. Watt, D.A. Nicoll-Griffith, and T.A. Baillie Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development Chem. Res. Toxicol. 17 2004 3 16 (Pubitemid 38134055)
19. S. Kumar, K. Mitra, K. Kassahun, and T.A. Baillie Approaches for minimizing metabolic activation of new drug candidates in drug discovery Handb. Exp. Pharmacol. 2010 511 544
20. T.A. Baillie, Drug metabolism in drug safety evaluation, in: D.A. Smith (Ed.), Encyclopedia of Drug Metabolism and Interactions, John Wiley & Sons, in press.
21. D.D. Christ, H. Satoh, J.G. Kenna, and L.R. Pohl Potential metabolic basis for enflurane hepatitis and the apparent cross-sensitization between enflurane and halothane Drug Metab. Dispos. 16 1988 135 140 (Pubitemid 18057109)
22. R.S. Obach, A.S. Kalomtkar, J.R. Soglia, and S.X. Zhao Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose Chem. Res. Toxicol. 21 2008 1814 1822
23. H. Takakusa, H. Masumoto, H. Yukinaga, C. Makino, S. Nakayama, O. Okazaki, and K. Sudo Covalent binding and tissue distribution/retention assessment of drugs associated with idiosyncratic drug toxicity Drug Metab. Dispos. 36 2008 1770 1779
24. J.N. Bauman, J.M. Kelly, S. Tripathy, S.X. Zhao, W.W. Lam, A.S. Kalgutkar, and R.S. Obach Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction Chem. Res. Toxicol. 22 2009 332 340
25. S. Nakayama, R. Atsumi, H. Takakusa, Y. Kobayashi, A. Kurihara, Y. Nagai, D. Nakai, and O. Okazaki A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding Drug Metab. Dispos. 37 2009 1970 1977
26. T. Usui, M. Mise, T. Hashizume, M. Yabuki, and S. Komuro Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins Drug Metab. Dispos. 37 2009 2383 2392
27. C. Lammert, S. Einarsson, C. Saha, A. Niklasson, E. Bjornsson, and N. Chalasani Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals Hepatology 47 2008 2003 2009 (Pubitemid 351945567)
28. H. Olson, G. Betton, D. Robinson, K. Thomas, A. Monro, G. Kolaja, P. Lilly, J. Sanders, G. Sipes, W. Bracken, M. Dorato, K. Van Deun, P. Smith, B. Berger, and A. Heller Concordance of the toxicity of pharmaceuticals in humans and in animals Regul. Toxicol. Pharmacol. 32 2000 56 67
29. A. Dash, W. Inman, K. Hoffmaster, S. Sevidal, J. Kelly, R.S. Obach, L.G. Griffith, and S.R. Tannenbaum Liver tissue engineering in the evaluation of drug safety Expert Opin. Drug Metab. Toxicol. 5 2009 1159 1174
30. M.J. Gomez-Lechon, A. Lahoz, L. Gombau, J.V. Castell, and M.T. Donato In vitro evaluation of potential hepatotoxicity induced by drugs Curr. Pharm. Des. 16 2010 1963 1977
31. D.M. Dambach, B.A. Andrews, and F. Moulin New technologies and screening strategies for hepatotoxicity: use of in vitro models Toxicol. Pathol. 33 2005 17 26 10.1080/01926230590522284 (Pubitemid 40216800)
32. M.L. Greer, T.J.D. Smith, and J.G. Kenna Mechanisms of drug hepatotoxicity in man: novel insights provided by the THLE-CYP cell panel Toxicology 262 2009 4 14 10.1016/j.tox.2009.04.047
33. J.W. Benbow, J. Aubrecht, M.J. Banker, D. Nettleton, and M.D. Aleo Predicting safety toleration of pharmaceutical chemical leads: cytotoxicity correlations to exploratory toxicity studies Toxicol. Lett. 197 2010 175 182 10.1016/j.toxlet.2010.05.016
34. J.A. Dykens, and Y. Will The significance of mitochondrial toxicity testing in drug development Drug Discov. Today 12 2007 777 785 10.1016/j.drudis.2007.07.013 (Pubitemid 47362789)
35. D. Pessayre, A. Mansouri, A. Berson, and B. Fromenty Mitochondrial involvement in drug-induced liver injury Handb. Exp. Pharmacol. 2010 311 365
36. B. Mannargudi, D. McNally, W. Reynolds, and J. Uetrecht Bioactivation of minocycline to reactive intermediates by myeloperoxidase, horseradish peroxidase, and hepatic microsomes: implications for minocycline-induced lupus and hepatitis Drug Metab. Dispos. 37 2009 1806 1818
37. G.A. Kullak-Ublick, B. Stieger, and P.J. Meier Enterohepatic bile salt transporters in normal physiology and liver disease Gastroenterology 126 2004 322 342 (Pubitemid 38040747)
38. P.J. Shaw, M.J. Hopfensperger, P.E. Ganey, and R.A. Roth Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha Toxicol. Sci. 100 2007 259 266 (Pubitemid 47617822)
39. J.F. Waring, M.J. Liguori, J.P. Luyendyk, J.F. Maddox, P.E. Ganey, R.F. Stachlewitz, C. North, E.A. Blomme, and R.A. Roth Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils J. Pharmacol. Exp. Ther. 316 2006 1080 1087 (Pubitemid 43345281)
40. A.H. Harrill, P.B. Watkins, S. Su, P.K. Ross, D.E. Harbourt, I.M. Stylianou, G.A. Boorman, M.W. Russo, R.S. Sackler, S.C. Harris, P.C. Smith, R. Tennant, M. Bogue, K. Paigen, C. Harris, T. Contractor, T. Wiltshire, I. Rusyn, and D.W. Threadgill Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans Genome Res. 19 2009 1507 1515 10.1101/gr.090241.108
41. W.L. Isley Hepatotoxicity of thiazolidinediones Expert Opin. Drug Saf. 2 2003 581 586 10.1517/14740338.2.6.581
42. T. Yokoi Troglitazone Handb. Exp. Pharmacol. 2010 419 435
43. S. Lloyd, M.J. Hayden, Y. Sakai, A. Fackett, P.M. Silber, N.J. Hewitt, and A.P. Li Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors Chem. Biol. Interact. 142 2002 57 71 (Pubitemid 35232553)
44. J. Gao, L. Ann Garulacan, S.M. Storm, S.A. Hefta, G.J. Opiteck, J.H. Lin, F. Moulin, and D.M. Dambach Identification of in vitro protein biomarkers of idiosyncratic liver toxicity Toxicol. In Vitro 18 2004 533 541 10.1016/j.tiv.2004.01.012 (Pubitemid 38591312)
45. A. Alfirevic, and M. Pirmohamed Adverse drug reactions and pharmacogenomics: recent advances Personalized Med. 5 2008 11 23